^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Marginal Zone Lymphoma
    Drug:Yescarta (axicabtagene ciloleucel) (CD19-targeted CAR-T immunotherapy)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Marginal Zone Lymphoma: Suggested treatment regimens…Anti-CD19 CAR T-cell therapy (only after ≥2 prior chemoimmunotherapy regimens…axicabtagene ciloleucel
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Kite Pharma Press Release
    Title:

    YESCARTA® IS FIRST CAR T-CELL THERAPY TO DEMONSTRATE HIGH RESPONSE RATES AND DURABLE CLINICAL BENEFIT IN A PIVOTAL INDOLENT NON-HODGKIN LYMPHOMA STUDY

    Published date:
    12/05/2020
    Excerpt:
    Kite, a Gilead Company...U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) and granted Priority Review designation for Yescarta for the treatment of relapsed or refractory follicular lymphoma (FL) and marginal zone lymphoma (MZL)...